Approval · Notice of Compliance 4467 · 1996

CRIXIVAN: Notice of Compliance 4467

Issued September 13, 1996

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 4467
Date: September 13, 1996
Company: Merck Sharp & Dohme
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Priority-NAS
Therapeutic class: Human immunodeficiency virus (hiv) protease inhibitor

Products in this notice

Brand	DIN	Status today
CRIXIVAN	02229153	—
CRIXIVAN	02229161	Cancelled Post Market
CRIXIVAN	02229188	Cancelled Pre Market
CRIXIVAN	02229196	Cancelled Post Market

Medicinal ingredients

INDINAVIR SULFATE 100 MG per CAP
INDINAVIR SULFATE 200 MG per CAP
INDINAVIR SULFATE 300 MG per CAP
INDINAVIR SULFATE 400 MG per CAP